Literature DB >> 14694092

Competitive fitness of nevirapine-resistant human immunodeficiency virus type 1 mutants.

Jennifer A Collins1, M Gregory Thompson, Elijah Paintsil, Melisa Ricketts, Joanna Gedzior, Louis Alexander.   

Abstract

Determining the fitness of drug-resistant human immunodeficiency virus type 1 (HIV-1) strains is necessary for the development of population-based studies of resistance patterns. For this purpose, we have developed a reproducible, systematic assay to determine the competitive fitness of HIV-1 drug-resistant mutants. To demonstrate the applicability of this assay, we tested the fitness of the five most common nevirapine-resistant mutants (103N, 106A, 181C, 188C, and 190A), with mutations in HIV-1 reverse transcriptase (RT), singly and in combination (for a total of 31 variants) in a defined HIV-1 background. For these experiments, the 27 RT variants that produced viable virus were cocultured with wild-type virus without nevirapine. The ratios of the viral species were determined over time by utilization of a quantitative real-time RT-PCR-based assay. These experiments revealed that all of the viable variants were less fit than the wild type and demonstrated that the order of relative fitness of the single mutants tested was as follows: 103N > 181C > 190A > 188C > 106A. This order correlated with the commonality of these mutants as a result of nevirapine monotherapy. These investigations also revealed that, on average, the double mutants were less fit than the single mutants and the triple mutants were less fit than the double mutants. However, the fitness of the single and double mutants was often not predictive of the fitness of the derivative triple mutants, suggesting the presence of complex interactions between the closely aligned residues that confer nevirapine resistance. This complexity was also evident from the observation that all three of the replication-competent quadruple mutants were fitter than most of the triple mutants, and in some cases, even the double mutants. Our data suggest that, in many cases, viral fitness is the determining factor in the evolution of nevirapine-resistant mutants in vivo, that interactions between the residues that confer nevirapine resistance are complex, and that these interactions substantially affect reverse transcriptase structure and/or function.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 14694092      PMCID: PMC368761          DOI: 10.1128/jvi.78.2.603-611.2004

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  50 in total

1.  In vitro analysis of human immunodeficiency virus type 1 resistance to nevirapine and fitness determination of resistant variants.

Authors:  Maria Dolores Iglesias-Ussel; Concepción Casado; Eloísa Yuste; Isabel Olivares; Cecilio López-Galíndez
Journal:  J Gen Virol       Date:  2002-01       Impact factor: 3.891

2.  Development of drug resistance in patients receiving combinations of zidovudine, didanosine and nevirapine.

Authors:  B Conway; M A Wainberg; D Hall; M Harris; P Reiss; D Cooper; S Vella; R Curry; P Robinson; J M Lange; J S Montaner
Journal:  AIDS       Date:  2001-07-06       Impact factor: 4.177

3.  Detection of replication-competent and pseudotyped human immunodeficiency virus with a sensitive cell line on the basis of activation of an integrated beta-galactosidase gene.

Authors:  J Kimpton; M Emerman
Journal:  J Virol       Date:  1992-04       Impact factor: 5.103

4.  Production of acquired immunodeficiency syndrome-associated retrovirus in human and nonhuman cells transfected with an infectious molecular clone.

Authors:  A Adachi; H E Gendelman; S Koenig; T Folks; R Willey; A Rabson; M A Martin
Journal:  J Virol       Date:  1986-08       Impact factor: 5.103

5.  Comparative fitness of multi-dideoxynucleoside-resistant human immunodeficiency virus type 1 (HIV-1) in an In vitro competitive HIV-1 replication assay.

Authors:  P Kosalaraksa; M F Kavlick; V Maroun; R Le; H Mitsuya
Journal:  J Virol       Date:  1999-07       Impact factor: 5.103

6.  Human immunodeficiency virus type 1 mutations selected in patients failing efavirenz combination therapy.

Authors:  L T Bacheler; E D Anton; P Kudish; D Baker; J Bunville; K Krakowski; L Bolling; M Aujay; X V Wang; D Ellis; M F Becker; A L Lasut; H J George; D R Spalding; G Hollis; K Abremski
Journal:  Antimicrob Agents Chemother       Date:  2000-09       Impact factor: 5.191

7.  Broad spectrum of in vivo fitness of human immunodeficiency virus type 1 subpopulations differing at reverse transcriptase codons 41 and 215.

Authors:  J Goudsmit; A de Ronde; E de Rooij; R de Boer
Journal:  J Virol       Date:  1997-06       Impact factor: 5.103

8.  Selection and fading of resistance mutations in women and infants receiving nevirapine to prevent HIV-1 vertical transmission (HIVNET 012).

Authors:  S H Eshleman; M Mracna; L A Guay; M Deseyve; S Cunningham; M Mirochnick; P Musoke; T Fleming; M Glenn Fowler; L M Mofenson; F Mmiro; J B Jackson
Journal:  AIDS       Date:  2001-10-19       Impact factor: 4.177

9.  In vitro intersubtype recombinants of human immunodeficiency virus type 1: comparison to recent and circulating in vivo recombinant forms.

Authors:  Miguel E Quiñones-Mateu; Yong Gao; Sarah C Ball; Andre J Marozsan; Awet Abraha; Eric J Arts
Journal:  J Virol       Date:  2002-10       Impact factor: 5.103

10.  Persistence of azidothymidine-resistant human immunodeficiency virus type 1 RNA genotypes in posttreatment sera.

Authors:  J Albert; J Wahlberg; J Lundeberg; S Cox; E Sandström; B Wahren; M Uhlén
Journal:  J Virol       Date:  1992-09       Impact factor: 5.103

View more
  46 in total

1.  Determinants of individual variation in intracellular accumulation of anti-HIV nucleoside analog metabolites.

Authors:  Elijah Paintsil; Ginger E Dutschman; Rong Hu; Susan P Grill; Chuan-Jen Wang; Wing Lam; Fang-Yong Li; Musie Ghebremichael; Veronika Northrup; Yung-Chi Cheng
Journal:  Antimicrob Agents Chemother       Date:  2010-11-15       Impact factor: 5.191

2.  Evaluation of a multiple-cycle, recombinant virus, growth competition assay that uses flow cytometry to measure replication efficiency of human immunodeficiency virus type 1 in cell culture.

Authors:  Carrie Dykes; Jiong Wang; Xia Jin; Vicente Planelles; Dong Sung An; Amanda Tallo; Yangxin Huang; Hulin Wu; Lisa M Demeter
Journal:  J Clin Microbiol       Date:  2006-06       Impact factor: 5.948

3.  Ultrasensitive detection of minor drug-resistant variants for HIV after nevirapine exposure using allele-specific PCR: clinical significance.

Authors:  Christopher F Rowley; Christian L Boutwell; Esther J Lee; Iain J MacLeod; Heather J Ribaudo; M Essex; Shahin Lockman
Journal:  AIDS Res Hum Retroviruses       Date:  2010-03       Impact factor: 2.205

4.  The fitness cost of mutations associated with human immunodeficiency virus type 1 drug resistance is modulated by mutational interactions.

Authors:  Mian-er Cong; Walid Heneine; J Gerardo García-Lerma
Journal:  J Virol       Date:  2006-12-27       Impact factor: 5.103

Review 5.  Adherence-resistance relationships to combination HIV antiretroviral therapy.

Authors:  David R Bangsberg; Deanna L Kroetz; Steven G Deeks
Journal:  Curr HIV/AIDS Rep       Date:  2007-05       Impact factor: 5.071

6.  Replicative capacity differences of thymidine analog resistance mutations in subtype B and C human immunodeficiency virus type 1.

Authors:  Kimberly L Armstrong; Tun-Hou Lee; M Essex
Journal:  J Virol       Date:  2009-02-18       Impact factor: 5.103

7.  Viral adaptation to an antiviral protein enhances the fitness level to above that of the uninhibited wild type.

Authors:  James E Cherwa; Pablo Sanchez-Soria; Holly A Wichman; Bentley A Fane
Journal:  J Virol       Date:  2009-09-02       Impact factor: 5.103

8.  From resistance to stimulation: the evolution of a virus in the presence of a dominant lethal inhibitory scaffolding protein.

Authors:  James E Cherwa; Bentley A Fane
Journal:  J Virol       Date:  2011-04-13       Impact factor: 5.103

9.  Human immunodeficiency virus type 1 resistance or cross-resistance to nonnucleoside reverse transcriptase inhibitors currently under development as microbicides.

Authors:  Philippe Selhorst; Ana C Vazquez; Katty Terrazas-Aranda; Johan Michiels; Katleen Vereecken; Leo Heyndrickx; Jan Weber; Miguel E Quiñones-Mateu; Kevin K Ariën; Guido Vanham
Journal:  Antimicrob Agents Chemother       Date:  2011-01-31       Impact factor: 5.191

10.  Rapid and persistent selection of the K103N mutation as a majority quasispecies in a HIV1-patient exposed to efavirenz for three weeks: a case report and review of the literature.

Authors:  Ennio Polilli; Giustino Parruti; Luana Cosentino; Federica Sozio; Annalisa Saracino; Augusta Consorte; Gioacchino Angarano; Francesco Di Masi; Elena Mazzotta; Paolo Fazii
Journal:  J Med Case Rep       Date:  2009-09-18
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.